Letrozole Synthon

Letrozole, the active ingredient in Letrozole Synthon, is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Early‑stage hormone receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence when given as adjuvant therapy. - Metastatic hormone receptor‑positive breast cancer in postmenopausal women: delays disease progression as first‑line endocrine therapy. - Neoadjuvant treatment of hormone receptor‑positive breast cancer: may shrink tumor size before surgery.

Adverse reactions may occur with letrozole therapy.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint pain: aching or stiffness in joints. - Fatigue: persistent tiredness not relieved by rest. - Nausea: sensation of queasiness, sometimes leading to vomiting.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes, hepatic failure. - Bone fracture: increased risk due to reduced estrogen protection of bone. - Pulmonary embolism: sudden shortness of breath, chest pain, possible circulatory compromise.

Patients should be monitored for specific safety considerations while on letrozole. - Bone health monitoring: assess bone mineral density periodically. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Cardiovascular risk evaluation: monitor blood pressure and lipid profile. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Caution with estrogen therapy: avoid concurrent use of estrogen‑containing products. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Letrozole may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels and effectiveness. - Concurrent estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering action.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may modestly increase letrozole concentrations. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Cholesterol‑lowering agents (e.g., statins): observe for any unexpected changes in lipid profile.